- Home
- HNVR vs OBIO Comparison
HNVR vs OBIO Comparison
Compare HNVR & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- OBIO
- Stock Information
- Founded
- HNVR 2008
- OBIO 2017
- Country
- HNVR United States
- OBIO United States
- Employees
- HNVR N/A
- OBIO N/A
- Industry
- HNVR Commercial Banks
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- HNVR Finance
- OBIO Health Care
- Exchange
- HNVR Nasdaq
- OBIO Nasdaq
- Market Cap
- HNVR 163.2M
- OBIO 151.3M
- IPO Year
- HNVR 2022
- OBIO N/A
- Fundamental
- Price
- HNVR $20.70
- OBIO $2.85
- Analyst Decision
- HNVR Buy
- OBIO Strong Buy
- Analyst Count
- HNVR 1
- OBIO 5
- Target Price
- HNVR $22.00
- OBIO $15.00
- AVG Volume (30 Days)
- HNVR 15.1K
- OBIO 69.1K
- Earning Date
- HNVR 04-29-2025
- OBIO 05-12-2025
- Dividend Yield
- HNVR 1.95%
- OBIO N/A
- EPS Growth
- HNVR N/A
- OBIO N/A
- EPS
- HNVR 1.66
- OBIO N/A
- Revenue
- HNVR $63,491,000.00
- OBIO $2,638,000.00
- Revenue This Year
- HNVR N/A
- OBIO $27.37
- Revenue Next Year
- HNVR $15.80
- OBIO $42.68
- P/E Ratio
- HNVR $12.47
- OBIO N/A
- Revenue Growth
- HNVR 5.04
- OBIO N/A
- 52 Week Low
- HNVR $13.62
- OBIO $2.49
- 52 Week High
- HNVR $27.14
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- HNVR 46.68
- OBIO 36.86
- Support Level
- HNVR $18.60
- OBIO $2.75
- Resistance Level
- HNVR $21.05
- OBIO $3.26
- Average True Range (ATR)
- HNVR 1.22
- OBIO 0.48
- MACD
- HNVR 0.08
- OBIO -0.01
- Stochastic Oscillator
- HNVR 50.00
- OBIO 16.82
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.